The European Commission has imposed a fine on Teva for abusing its dominant position in the market for glatiramer acetate, a medication used to treat multiple sclerosis. Teva’s tactics, which included manipulating the patent system and disseminating misleading information about a competing product, were capable of delaying price competition and likely allowed Teva to maintain supra-competitive profits. The article provides a brief overview of the Commission’s decision and of how it tackled p
...THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 216.73.216.161
Please verify email or join us to access premium content!